Literature DB >> 16326253

Initial approach to the patient who has chest pain.

Luis H Haro1, Wyatt W Decker, Eric T Boie, R Scott Wright.   

Abstract

The last decade has seen extraordinary advances in the cardiovascular arena, particularly in the evaluation and management of the patient who has acute coronary syndromes. From bedside markers of myocardial damage to drug-eluting stents, technical advances are proliferating. Efforts in developing an international registry for acute aortic dissection have helped elucidate the acute presentation, management, and prognosis of this uncommon but lethal disease. Finally, the multiple research efforts in coordinating clinical decision-making with serologic markers and advanced imaging for the diagnosis of pulmonary embolism is changing the approach to the patient at risk for thromboembolic disease.

Entities:  

Mesh:

Year:  2006        PMID: 16326253     DOI: 10.1016/j.ccl.2005.09.007

Source DB:  PubMed          Journal:  Cardiol Clin        ISSN: 0733-8651            Impact factor:   2.213


  3 in total

1.  Age and clinical outcomes in patients presenting with acute coronary syndromes.

Authors:  Emad Ahmed; Khalid F Alhabib; Ayman El-Menyar; Nidal Asaad; Kadhim Sulaiman; Ahmad Hersi; Wael Almahmeed; Alawi A Alsheikh-Ali; Haitham Amin; Ahmed Al-Motarreb; Shukri Al Saif; Rajvir Singh; Jawad Al-Lawati; Jassim Al Suwaidi
Journal:  J Cardiovasc Dis Res       Date:  2013-06-21

2.  A Heart Rate-Dependent Protocol of "One-Stop" Computed Tomography Angiography of Coronary Combined with Pulmonary Arteries Reduces the Dosages of Contrast Agent.

Authors:  Hairong Yu; Hui Wang; Zhen Gao; Guoyue Chen; Hao Song; Shihao Yan; Xiaomei Luan; Peiji Song
Journal:  Dose Response       Date:  2022-06-29       Impact factor: 2.623

3.  Shifting up cutoff value of d-dimer in the evaluation of pulmonary embolism: a viable option? Possible risks and benefits.

Authors:  Bennidor Raviv; Shlomo H Israelit
Journal:  Emerg Med Int       Date:  2012-07-24       Impact factor: 1.112

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.